Medications

Ramucirumab in stomach cancer: Added benefit not proven

Ramucirumab (trade name: Cyramza) is a monoclonal antibody, which blocks a receptor, reducing the growth of blood vessels and so reducing blood supply to the tumours. This aims to slow the growth of the tumours. As a so-called ...

Medications

Nivolumab in renal cell cancer: Indication of added benefit

Nivolumab has been approved since April 2016 as a checkpoint inhibitor for the treatment of adults with advanced renal cell cancer who have already undergone prior therapy. In an early benefit assessment, the German Institute ...

Medications

Ospemifene in vulvovaginal atrophy: Added benefit not proven

Ospemifene (tradename: Senshio) is approved for the treatment of moderate to severe symptomatic vulvovaginal atrophy (VVA) in post-menopausal women who are not candidates for local vaginal oestrogen therapy. The drug has ...

Medications

Umeclidinium for symptom relief in COPD: Added benefit not proven

Umeclidinium bromide (umeclidinium for short) has been approved since 2014 as a maintenance bronchodilator treatment in adults with chronic obstructive pulmonary disease (COPD) and was initially only available in combination ...

Medications

Mepolizumab in severe asthma: Added benefit not proven

The monoclonal antibody mepolizumab has been approved since the end of 2015 for the treatment of adults with severe refractory eosinophilic asthma. The German Institute for Quality and Efficiency in Health Care (IQWiG) now ...

page 2 from 3